69.05 0.00 (0.00%)
After hours: 5:30PM EDT
|Bid||65.00 x 800|
|Ask||75.00 x 1400|
|Day's Range||68.31 - 69.33|
|52 Week Range||60.23 - 140.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.85|
Jonathan Corpina of Meridian Equity Partners joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest moves.
NEW YORK, Aug. 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United ...
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Over the last month, growth of ETFs holding INCY is favorable, with net inflows of $19.82 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Of course, it's difficult to predict which technologies will change our world and how long their influence will last. On top of that, it's often a challenge for investors to identify investable opportunities associated with these groundbreaking technologies. The Morningstar Exponential Technologies Index focuses on finding high-growth companies that are in the early stages of developing technologies that are expected to have a broad impact on society and transform how we live and work.
The only name of consequence that headed meaningfully higher was DISH Network (NASDAQ:DISH), up 14.5% in response to its second-quarter report. Heading into the new trading week, those appear to be Entergy (NYSE:ETR), Incyte (NASDAQ:INCY) and SL Green Realty (NYSE:SLG). When Entergy reported better-than-expected second-quarter earnings last week, the stock jumped.
DaVita (DVA) released its second-quarter earnings after the market closed on August 1. It surpassed Wall Street analysts’ estimates for revenues and EPS and reported non-GAAP EPS of $1.15 on revenues of $2.9 billion. The EPS estimate was $0.97 on revenues of $2.8 billion.
Incyte INCY reported strong second-quarter results, with Jakafi posting 25% year-over-year revenue growth in the United States and Iclusig royalties up 27%. Jakafi sales were slightly above our expectations, but we are maintaining our full-year outlook for the drug, on the lower end of management guidance, and reaffirming our fair value estimate of $97 per share. The cash-generating Jakafi franchise underpins our narrow economic moat rating, as we believe Incyte's entrenched position in the myeloproliferative neoplasm market and the future opportunities for expansion will allow the company to continue earning excess returns.
Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018, compared to estimates for EPS of $0.34 on revenues of $473.8 million.
Incyte (INCY) delivered earnings and revenue surprises of -13.33% and 12.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Wilmington, Delaware-based company said it had profit of 24 cents. Earnings, adjusted for one-time gains and costs, were 26 cents per share. The results missed Wall Street expectations. ...
WILMINGTON, Del.-- -- Total product-related revenues of $421 million in Q2 2018, representing 29 percent growth over the same period last year; Jakafi ® revenues of $346 million in Q2 2018, representing 25 percent growth over the same period last year Pivotal REACH1 study of Jakafi in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in Q3 2018 Later-stage portfolio provides ...
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Incyte Corporation (NASDAQ: INCY ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 8:00 AM Eastern Time. To ...
Incyte (INCY) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS at $0.34 on revenues of $473.8 million in Q2 2018.
Gilead Sciences could swipe its next chief executive from privately held Dermavant or seek a major merger with Vertex Pharmaceuticals or Dow Jones' Pfizer, investors suggested.
Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.
Cancer. The mere mention of the word can drudge up discomfort, as most everyone knows it's second only to heart disease when it comes to claiming lives. Unlike heart disease, though, cancer is difficult to prevent and similarly difficult to fight. The battle against the myriad forms of cancer, however, also is an opportunity for investors - namely, in health care stocks. Sales of drugs used to fight the disease are expected to exceed $160 billion by 2021. But because there are so many different types of cancer, that revenue has been and will continue to be widely distributed among the pharmaceutical makers of superior cancer-fighting solutions. Here's a rundown of the market's top cancer-fighting health care stocks. They come in all shapes and sizes. Some are tightly focused - perhaps only making one drug - while some are arguably overly diversified. In all cases, however, a cancer treatment has the potential to be a game-changer - not just for investors, but for cancer patients as well. SEE ALSO: 25 Stocks Every Retiree Should Own
INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 ...